SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

ARLINGTON, Mass., Nov. 16, 2026 // -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a busin…

ELOX

Related stories